Opportunity Information: Apply for RFA HG 21 029
The National Institutes of Health (NIH) funding opportunity RFA HG 21 029 supports the launch of a new research program called Molecular Phenotypes of Null Alleles in Cells (MorPhiC). The basic idea behind MorPhiC is to build a consistent, widely usable catalog that shows what happens to cells when individual human genes are knocked out (that is, converted into null alleles with loss of function) and then examined through a range of molecular and cellular readouts. The program is explicitly focused on in vitro multicellular systems, with the intent that the resulting dataset becomes a broadly accessible community resource for biomedical research, enabling researchers to compare gene knockouts across standardized assays and platforms.
This particular FOA funds Phase 1 Data Production Research and Development Centers under a UM1 cooperative agreement mechanism (meaning NIH expects substantial scientific and programmatic involvement during the award). Phase 1 is designed as a proving and optimization stage rather than a final, full-scale production effort. Across the overall MorPhiC program, Phase 1 targets a shared subset of 1,000 protein-coding genes. The goal is to use that common gene set to evaluate, refine, and stress-test methods for generating null alleles and for measuring the downstream phenotypic consequences in ways that can later be scaled up toward the long-term objective of covering essentially every human gene.
The Data Production Research and Development Centers supported by this announcement are expected to develop and operate diverse experimental systems and phenotyping assays, and to explore multiple approaches for producing MorPhiC data at scale. In practical terms, that means awardees are meant to (1) generate gene knockouts efficiently and reproducibly, (2) measure a rich set of phenotypic effects using molecular and cellular assays, and (3) compare and evaluate the strengths, weaknesses, throughput, cost, and data quality of different strategies. A major emphasis is not just on producing data, but on maximizing its informativeness: selecting or inventing assays and multicellular in vitro models that capture meaningful biology and that can support reliable cross-gene and cross-site comparisons.
Phase 1 also has a strong methods and infrastructure component. The FOA highlights the need to assess scale limitations (for example, bottlenecks in editing, culturing, assay throughput, or analysis pipelines), to develop common data formats so that results from different centers can be integrated, and to establish concrete use cases that demonstrate how the catalog will be applied by outside researchers. In other words, the program is meant to standardize how null-allele phenotypes are generated, recorded, shared, and interpreted, so that the eventual resource is consistent rather than a patchwork of incompatible datasets.
This opportunity falls under the NIH health activity category and is associated with CFDA 93.172. It does not allow clinical trials, reinforcing that the work should remain preclinical and in vitro. The eligible applicant pool is broad and includes many types of U.S. organizations and governmental entities, such as state, county, and local governments; public and private institutions of higher education; independent school districts; special district governments; and public housing authorities/Indian housing authorities. It also includes federally recognized Native American tribal governments and other tribal organizations, nonprofits with or without 501(c)(3) status (as long as they are not institutions of higher education in those categories), for-profit organizations (other than small businesses) and small businesses. The FOA also explicitly notes additional eligible applicant categories such as HBCUs, Hispanic-serving institutions, AANAPISIs, Alaska Native and Native Hawaiian serving institutions, tribally controlled colleges and universities, faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-U.S. (foreign) entities.
Administratively, the original closing date listed for applications was November 1, 2021, and the funding instrument is a cooperative agreement (UM1), signaling a coordinated, multi-site program structure with NIH involvement. While the excerpt does not specify an award ceiling or number of expected awards, the structure and language make clear that NIH intended to fund multiple centers that could collectively test different systems and assay approaches, converge on shared standards, and generate an initial, integrated dataset on the common 1,000-gene subset that would inform later phases of MorPhiC.Apply for RFA HG 21 029
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase 1: Data Production Research and Development Centers (UM1)(Clinical trials not allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172.
- This funding opportunity was created on 2021-08-06.
- Applicants must submit their applications by 2021-11-01. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Browse more opportunities from the same category: Health
Next opportunity: High-Resolution Exploration of the Human Islet Tissue Environment [HIRN Human Pancreas Analysis Consortium (HPAC)] (U01 - Clinical Trial Not Allowed)
Previous opportunity: NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HG 21 029
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HG 21 029) also looked into and applied for these:
| Funding Opportunity |
|---|
| Reducing Racial and Ethnic Healthcare Disparities in Chronic Conditions by Dissemination and Implementation of Patient Centered Outcomes Research (PCOR) Evidence (R18) Apply for RFA HS 22 001 Funding Number: RFA HS 22 001 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $1,500,000 |
| Resource Center for Tribal Epidemiological Centers (RC-TEC) (U24 Clinical Trial Not Allowed) Apply for RFA MD 21 003 Funding Number: RFA MD 21 003 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Clinical and Biological Measures of TBI-related Dementia Including Chronic Traumatic Encephalopathy (R01 Clinical Trial Not Allowed) Apply for PAR 22 024 Funding Number: PAR 22 024 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Creating an Educational Nexus for Training in Experimental Rigor (CENTER) (UC2 Clinical Trial Not Allowed) Apply for RFA NS 21 009 Funding Number: RFA NS 21 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Dementia Care and Caregiver Support Intervention Research (R01 Clinical Trial Required) Apply for PAR 21 307 Funding Number: PAR 21 307 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pragmatic Trials for Dementia Care and Caregiver Support (R61/R33 Clinical Trial Required) Apply for PAR 21 308 Funding Number: PAR 21 308 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Feasibility Studies that Explore Healthy and Diseased Temporomandibular Joints (TMJ) using Single Cell Multi-Omic Analyses (UH2/UH3 Clinical Trial Not Allowed) Apply for RFA DE 22 005 Funding Number: RFA DE 22 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed) Apply for PAR 21 316 Funding Number: PAR 21 316 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Genome Sequencing Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed) Apply for RFA RM 21 013 Funding Number: RFA RM 21 013 Agency: National Institutes of Health Category: Health Funding Amount: $7,200,000 |
| Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed) Apply for PAR 22 026 Funding Number: PAR 22 026 Agency: National Institutes of Health Category: Health Funding Amount: $499,000 |
| Deciphering Immune-CNS interactions in HIV utilizing in-vitro and in-vivo model systems (R21 Clinical Trial Not Allowed) Apply for RFA MH 21 251 Funding Number: RFA MH 21 251 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Deciphering Immune-CNS interactions in people living with HIV on Anti-Retroviral therapy (R01 Clinical Trial Optional) Apply for RFA MH 21 250 Funding Number: RFA MH 21 250 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Prevention and Alcohol (R01 Clinical Trials Optional) Apply for RFA AA 21 016 Funding Number: RFA AA 21 016 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| HIV Prevention and Alcohol (R34 Clinical Trials Optional) Apply for RFA AA 21 017 Funding Number: RFA AA 21 017 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional) Apply for PAR 21 282 Funding Number: PAR 21 282 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Continued Development of the Gabriella Miller Kids First Pediatric Data Resource Center (U2C Clinical Trial Not Allowed) Apply for RFA RM 21 014 Funding Number: RFA RM 21 014 Agency: National Institutes of Health Category: Health Funding Amount: $4,000,000 |
| Tanzania Malaria Case Management Activity (TMCM) Apply for RFI 621 21 HO 001 Funding Number: RFI 621 21 HO 001 Agency: Tanzania USAID-Dar es Salaam Category: Health Funding Amount: Case Dependent |
| HEAL Initiative: Interdisciplinary Teams to Elucidate the Mechanisms of Device-Based Pain Relief (RM1 Clinical Trial Optional) Apply for RFA NS 22 016 Funding Number: RFA NS 22 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) Apply for PAR 21 317 Funding Number: PAR 21 317 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed) Apply for PAR 22 029 Funding Number: PAR 22 029 Agency: National Institutes of Health Category: Health Funding Amount: $630,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HG 21 029", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.